Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Aevi Genomic Medicine

DB:2MJ
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2MJ
DB
$14M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The last earnings update was 81 days ago. More info.


Add to Portfolio Compare Print
  • Aevi Genomic Medicine has significant price volatility in the past 3 months.
2MJ Share Price and Events
7 Day Returns
-9.3%
DB:2MJ
-2.9%
DE Biotechs
-3.9%
DE Market
1 Year Returns
-16.9%
DB:2MJ
8.7%
DE Biotechs
10.6%
DE Market
2MJ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aevi Genomic Medicine (2MJ) -9.3% -14.5% 16.7% -16.9% -96.8% -
DE Biotechs -2.9% -4.1% 8.9% 8.7% 48.6% 14.3%
DE Market -3.9% -2.1% -0.4% 10.6% 2.9% 4.2%
1 Year Return vs Industry and Market
  • 2MJ underperformed the Biotechs industry which returned 8.7% over the past year.
  • 2MJ underperformed the Market in Germany which returned 10.6% over the past year.
Price Volatility
2MJ
Industry
5yr Volatility vs Market
Related Companies

2MJ Value

 Is Aevi Genomic Medicine undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Aevi Genomic Medicine is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Aevi Genomic Medicine has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Aevi Genomic Medicine. This is due to cash flow or dividend data being unavailable. The share price is €0.147.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aevi Genomic Medicine's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aevi Genomic Medicine's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2MJ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.30
NasdaqCM:GNMX Share Price ** NasdaqCM (2020-02-03) in USD $0.17
Europe Biotechs Industry PE Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 36.32x
Germany Market PE Ratio Median Figure of 403 Publicly-Listed Companies 20.52x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aevi Genomic Medicine.

DB:2MJ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:GNMX Share Price ÷ EPS (both in USD)

= 0.17 ÷ -0.30

-0.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aevi Genomic Medicine is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Aevi Genomic Medicine is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Aevi Genomic Medicine's expected growth come at a high price?
Raw Data
DB:2MJ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 0.93x
Germany Market PEG Ratio Median Figure of 263 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aevi Genomic Medicine, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aevi Genomic Medicine's assets?
Raw Data
DB:2MJ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $-0.05
NasdaqCM:GNMX Share Price * NasdaqCM (2020-02-03) in USD $0.17
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.79x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.85x
DB:2MJ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:GNMX Share Price ÷ Book Value per Share (both in USD)

= 0.17 ÷ -0.05

-3.11x

* Primary Listing of Aevi Genomic Medicine.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aevi Genomic Medicine has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at our analysis of 2MJ’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Aevi Genomic Medicine's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Aevi Genomic Medicine's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Aevi Genomic Medicine has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2MJ Future Performance

 How is Aevi Genomic Medicine expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aevi Genomic Medicine has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
39.3%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aevi Genomic Medicine expected to grow at an attractive rate?
  • Unable to compare Aevi Genomic Medicine's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Aevi Genomic Medicine's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Aevi Genomic Medicine's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:2MJ Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 39.3%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 29.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2MJ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2MJ Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:2MJ Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 -19 -19
2019-06-30 -21 -22
2019-03-31 -25 -27
2018-12-31 -27 -31
2018-09-30 -27 -31
2018-06-30 -29 -33
2018-03-31 -30 -33
2017-12-31 -33 -35
2017-09-30 -32 -36
2017-06-30 -32 -38
2017-03-31 -34 -42
2016-12-31 -33 -42

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Aevi Genomic Medicine is high growth as no earnings estimate data is available.
  • Unable to determine if Aevi Genomic Medicine is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2MJ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Aevi Genomic Medicine Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2MJ Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:2MJ Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.30
2019-06-30 -0.35
2019-03-31 -0.43
2018-12-31 -0.50
2018-09-30 -0.53
2018-06-30 -0.62
2018-03-31 -0.69
2017-12-31 -0.83
2017-09-30 -0.97
2017-06-30 -1.02
2017-03-31 -1.15
2016-12-31 -1.19

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aevi Genomic Medicine will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 2MJ’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Aevi Genomic Medicine's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Aevi Genomic Medicine's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Aevi Genomic Medicine's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aevi Genomic Medicine has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2MJ Past Performance

  How has Aevi Genomic Medicine performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aevi Genomic Medicine's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aevi Genomic Medicine does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Aevi Genomic Medicine's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aevi Genomic Medicine's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Aevi Genomic Medicine's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aevi Genomic Medicine Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2MJ Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 -19.15 6.45 12.77
2019-06-30 -22.36 7.09 15.39
2019-03-31 -26.91 8.17 18.91
2018-12-31 -30.78 8.66 22.30
2018-09-30 -31.31 8.75 22.70
2018-06-30 -32.66 8.85 23.87
2018-03-31 -32.51 8.71 23.79
2017-12-31 -34.71 9.52 25.18
2017-09-30 -36.04 11.00 25.05
2017-06-30 -38.00 10.77 26.28
2017-03-31 -41.68 11.35 29.35
2016-12-31 -41.90 12.55 28.36
2016-09-30 -39.88 11.30 27.54
2016-06-30 -45.84 12.25 24.21
2016-03-31 -40.21 13.20 18.49
2015-12-31 -37.99 12.95 15.44
2015-09-30 -37.73 13.26 14.90
2015-06-30 -24.24 12.57 12.27
2015-03-31 -22.00 11.54 10.01
2014-12-31 -18.43 10.69 8.25
2014-09-30 -17.45 12.09 6.55
2014-06-30 -20.55 12.34 7.33
2014-03-31 -18.81 11.07 7.41
2013-12-31 -17.13 10.52 7.30
2013-09-30 -14.31 8.29 7.30
2013-06-30 -11.19 7.20 6.57
2013-03-31 -16.04 8.38 6.89

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aevi Genomic Medicine has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Aevi Genomic Medicine has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aevi Genomic Medicine improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Aevi Genomic Medicine's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aevi Genomic Medicine has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2MJ Health

 How is Aevi Genomic Medicine's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aevi Genomic Medicine's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aevi Genomic Medicine's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Aevi Genomic Medicine's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aevi Genomic Medicine's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Aevi Genomic Medicine has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aevi Genomic Medicine Company Filings, last reported 4 months ago.

DB:2MJ Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 -3.46 0.00 2.38
2019-06-30 0.33 0.00 3.44
2019-03-31 3.72 0.00 6.95
2018-12-31 7.93 0.00 12.08
2018-09-30 13.75 0.00 19.60
2018-06-30 15.29 0.00 19.15
2018-03-31 22.70 0.00 26.52
2017-12-31 30.62 0.00 33.73
2017-09-30 10.09 0.00 14.96
2017-06-30 17.82 0.00 21.36
2017-03-31 25.08 0.00 29.20
2016-12-31 34.98 0.00 39.84
2016-09-30 42.83 0.00 47.26
2016-06-30 51.38 0.00 53.69
2016-03-31 41.61 0.00 43.89
2015-12-31 50.35 0.00 53.06
2015-09-30 9.18 0.00 17.73
2015-06-30 20.99 0.00 22.01
2015-03-31 23.90 0.00 25.16
2014-12-31 29.66 0.00 33.29
2014-09-30 12.31 0.00 14.71
2014-06-30 13.70 0.00 16.43
2014-03-31 15.59 0.00 19.14
2013-12-31 18.42 0.00 22.39
2013-09-30 21.95 0.00 26.79
2013-06-30 27.07 0.00 28.98
2013-03-31 28.54 0.00 32.46
  • Aevi Genomic Medicine has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Aevi Genomic Medicine's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aevi Genomic Medicine has less than a year of cash runway based on current free cash flow.
  • Aevi Genomic Medicine has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.5% each year.
X
Financial health checks
We assess Aevi Genomic Medicine's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aevi Genomic Medicine has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2MJ Dividends

 What is Aevi Genomic Medicine's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aevi Genomic Medicine dividends.
If you bought €2,000 of Aevi Genomic Medicine shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aevi Genomic Medicine's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aevi Genomic Medicine's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2MJ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.7%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2MJ Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aevi Genomic Medicine has not reported any payouts.
  • Unable to verify if Aevi Genomic Medicine's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aevi Genomic Medicine's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aevi Genomic Medicine has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Aevi Genomic Medicine's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.7%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aevi Genomic Medicine afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aevi Genomic Medicine has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2MJ Management

 What is the CEO of Aevi Genomic Medicine's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Cola
COMPENSATION $1,331,623
AGE 59
TENURE AS CEO 6.4 years
CEO Bio

Mr. Michael F. Cola, also known as Mike, has been the Chief Executive Officer, President and Director of Aevi Genomic Medicine, Inc. since September 13, 2013. Mr. Cola is an Independent Director of Phathom Pharmaceuticals, Inc. since September 2019. He served as an Executive Officer at Shire plc since April 2, 2012. Mr. Cola served as the President of Specialty Pharmaceuticals at Shire Limited from 2007 until April 2012. Mr. Cola served as an Executive Vice President for Global Therapeutic Area Business Units at Shire Limited since July 2005. He was responsible for leading Shire's therapeutic teams, which were created last year to ensure effective management of Shire's existing products and to help identify and add new products to its pipeline. He served as the Managing Director of Corporate Operations for Safeguard Scientifics Inc. a holding company of Laureate Pharma, Inc. since January 2002 and served as Group President of Life Sciences from May 2004 to June 2005. He joined Safeguard in February 2000 as its Vice President of operations and management services. He served as a Managing Director of HealthCare and Life Sciences of Safeguard Scientifics, Inc. He spent eight years from 1992 to 2000 at AstraMerck/AstraZeneca, where he served as a Vice President of Global Clinical Operations and responsible for global clinical & U.S. product development operations & technology solutions integration, product development, medical affairs, business research, licensing and pharmaceutical business units. He worked at the Campbell Soup Company in manufacturing and product development. Mr. Cola served as the Chief Executive Officer of Clarient Inc. and served as its Interim Chief Executive Officer from February 2004 to July 2004. He has over 20 years of drug development and research & development experience. He spent four years in clinical and pre-clinical research at the University of Pennsylvania. He served as Chairman of NuPathe Inc. since December 2006 and has been its Director since January 16, 2007. Mr. Cola served as the Chairman of Clarient Inc. since June 16, 2003 and its Director since July 2000. He served as Chairman of Laureate Pharma. He has been an Independent Director of Vanda Pharmaceuticals, Inc., since June 2012. He has been a Director at Sage Therapeutics, Inc. since September 2014. He served as a Director of Ventaira Pharmaceuticals Inc. He serves as a Director of The Pennsylvania Biotechnology Association. He served as a Director of Sotas, Inc. and Mi8 Corporation. He served as a Director of Mantas, Inc. Mr. Cola holds a BA Degree in Biology and Physics from Ursinus College and a Masters of Science in Biomedical Engineering and Sciences from Drexel University.

CEO Compensation
  • Mike's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Mike's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Aevi Genomic Medicine management team in years:

5.6
Average Tenure
59
Average Age
  • The average tenure for the Aevi Genomic Medicine management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Mike Cola

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
59
TENURE
6.4 yrs

Garry Neil

TITLE
Chief Scientific Officer
COMPENSATION
$866K
AGE
65
TENURE
5.6 yrs

Mike McInaw

TITLE
CFO & Controller
AGE
31
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the Aevi Genomic Medicine board of directors in years:

6.7
Average Tenure
63
Average Age
  • The tenure for the Aevi Genomic Medicine board of directors is about average.
Board of Directors

Sol Barer

TITLE
Non-Executive Chairman
COMPENSATION
$72K
AGE
72
TENURE
7.6 yrs

Mike Cola

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
59
TENURE
6.4 yrs

Alastair John Clemow

TITLE
Independent Director
COMPENSATION
$70K
AGE
67
TENURE
9.5 yrs

Joe Grano

TITLE
Independent Director
COMPENSATION
$66K
AGE
71
TENURE
6.9 yrs

Barbara Duncan

TITLE
Independent Director
COMPENSATION
$81K
AGE
54
TENURE
4.6 yrs

Gene Bauer

TITLE
Independent Director
COMPENSATION
$58K
AGE
77
TENURE
18.9 yrs

Stephen Spielberg

TITLE
Member of Scientific Advisory Board
TENURE
4.3 yrs

Hákon Hákonarson

TITLE
Member of Advisory Board
AGE
58

Matt Bayley

TITLE
Director
COMPENSATION
$61K
AGE
43
TENURE
2.2 yrs
Who owns this company?
Recent Insider Trading
  • Information is not available.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
09. Dec 19 Sell Sol Barer Individual 05. Dec 19 05. Dec 19 -4,098,752 €0.12 €-494,639
09. Dec 19 Buy Michael Cola Individual 05. Dec 19 05. Dec 19 2,049,376 €0.12 €247,320
09. Dec 19 Buy Garry Neil Individual 05. Dec 19 05. Dec 19 2,049,376 €0.12 €247,320
X
Management checks
We assess Aevi Genomic Medicine's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aevi Genomic Medicine has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2MJ News

Simply Wall St News

2MJ Company Info

Description

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidate is AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn’s disease. The company also develops AEVI-005, a monoclonal antibody, which is in preclinical research program for the treatment of auto-immune pediatric disease. In addition, it focuses on evaluating the anti-seizure activity of AEVI-004 in a preclinical model as part of the National Institutes of Health Epilepsy Treatment Screening Program. It has a development and option agreement with Kyowa Hakko Kirin Co., Ltd. related to AEVI-002 and AEVI-005. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Details
Name: Aevi Genomic Medicine, Inc.
2MJ
Exchange: DB
Founded: 2000
$13,001,165
77,713,782
Website: http://www.aevigenomics.com
Address: Aevi Genomic Medicine, Inc.
435 Devon Park Drive,
Suite 715,
Wayne,
Pennsylvania, 19087,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM GNMX Common Shares Nasdaq Capital Market US USD 16. Jan 2009
DB 2MJ Common Shares Deutsche Boerse AG DE EUR 16. Jan 2009
Number of employees
Current staff
Staff numbers
14
Aevi Genomic Medicine employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/02/03 22:45
End of day share price update: 2020/02/03 00:00
Last estimates confirmation: 2019/03/29
Last earnings filing: 2019/11/14
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.